GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aileron Therapeutics
Aileron, a biotech company, shares reflect its complex history and shifting strategy. Their price trajectory is volatile and dependent on news about its new drug developments, as the company tries to find its way after previous setbacks.
Share prices of companies in the market segment - Oncology targeted therapy
Aileron Therapeutics is a biopharmaceutical company developing drugs that protect healthy cells from the side effects of chemotherapy. We've classified it in the "Targeted Oncology" segment. The chart below shows how the market values companies that improve the tolerability of cancer treatments.
Broad Market Index - GURU.Markets
Aileron Therapeutics is an oncology company developing drugs that protect healthy cells from the side effects of chemotherapy. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ALRN - Daily change in the company's share price Aileron Therapeutics
Aileron Therapeutics' daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the clinical trials of its oncology drugs.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein to protect patients from the side effects of chemotherapy. Oncology is a volatile sector. The chart below shows the average fluctuations in this industry, providing context for evaluating ALRN stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Aileron Therapeutics is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aileron Therapeutics
Aileron Therapeutics' year-to-date performance tells the story of its strategic pivot. Its 12-month market cap reflects its decision to focus on developing new drugs for lung diseases after the failure of its oncology programs. Its valuation is a bet on success in a new, promising field.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
Aileron Therapeutics is a clinical-stage biotech. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector, compared to big pharma, whose performance is more stable.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aileron Therapeutics, a biotech company developing a new class of drugs to protect healthy cells during chemotherapy, aims to improve the quality of life for cancer patients. Its annual market capitalization growth is entirely dependent on clinical data supporting its innovative approach.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aileron Therapeutics
Aileron is an oncology company. Its monthly performance is typical for early-stage biotech companies: it depends entirely on progress in its scientific developments. News about preclinical studies, patents, and funding are the main catalysts.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein to protect healthy cells from damage during chemotherapy. The chart below reflects the general sentiment in the targeted oncology sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aileron Therapeutics is a clinical-stage oncology company. Its shares are a classic biotech venture capital investment. Their value is determined not by general market trends, but by progress in clinical trials. This is a high-risk bet on the success of a specific scientific approach.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aileron Therapeutics
Shares of Aileron Therapeutics, an oncology company, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials of their targeted drugs, which are designed to protect the body during chemotherapy. The chart below is a clear example of how short-term scientific data shapes value in innovative medicine.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
Aileron Therapeutics is developing a new class of drugs to protect healthy cells during chemotherapy. This could change approaches to cancer treatment. The chart below shows how expectations for this potentially revolutionary technology are creating its own highly volatile trend for the company's stock.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aileron Therapeutics is a biotech company. This chart shows how its weekly performance, like that of other biotechs, is detached from the market. Its stock price is driven by clinical trial news and regulatory decisions, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
ALRN - Market capitalization of the company Aileron Therapeutics
The chart for Aileron Therapeutics' valuation reflects its shift in strategy and focus on treating rare diseases. Its current market cap reflects not so much the value of its development work as its cash balance and speculative expectations for the company's success with its new candidates.
ALRN - Share of the company's market capitalization Aileron Therapeutics within the market segment - Oncology targeted therapy
Aileron Therapeutics's stake in oncology is a bet on a new class of drugs that protect healthy cells from chemotherapy. Its market share reflects the potential of its approach to improving the tolerability of cancer treatments, which could be a valuable addition to existing therapies.
Market capitalization of the market segment - Oncology targeted therapy
Here's a chart of the total market capitalization of biotech companies developing targeted cancer therapies. Aileron Therapeutics is one of the players in this field. The chart's dynamics reflect the high volatility and risks associated with clinical trials in this complex field.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market value of a new approach to chemotherapy. Aileron Therapeutics' market cap is based on its drugs that protect healthy cells during cancer treatment. The line shows how this scientific idea, aimed at improving patients' quality of life, is competing for its share of the global oncology market.
Book value capitalization of the company, segment and market as a whole
ALRN - Book value capitalization of the company Aileron Therapeutics
The graph below shows the scientific foundation of Aileron Therapeutics. Its line reflects the value of intellectual property for drugs that stabilize the p53 protein, a promising approach for cancer treatment. The dynamics reflect the company's clinical research activity, which is its main asset.
ALRN - Share of the company's book capitalization Aileron Therapeutics within the market segment - Oncology targeted therapy
Aileron Therapeutics' tangible assets include its R&D infrastructure for developing a new class of drugs that protect cells from chemotherapy. The chart shows its share of this scientific base, which is the foundation for improving cancer treatment.
Market segment balance sheet capitalization - Oncology targeted therapy
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Aileron Therapeutics, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Aileron Therapeutics is developing a new class of drugs that "stabilize" proteins to fight cancer. The company's assets aren't factories, but a unique scientific platform and patent portfolio. The chart below illustrates the financial weight behind this effort to create a "protein shield" for healthy cells.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aileron Therapeutics
Aileron Therapeutics is working on a new class of cancer drugs. Its value lies in its scientific platform, not its manufacturing facilities. The chart below is a visualization of the venture capital bet. Market capitalization is virtually unrelated to book value and is a barometer of investor confidence in the breakthrough potential of its technology.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
Aileron Therapeutics, Inc. is a biotech company developing a new class of drugs to protect against the side effects of chemotherapy. Its value lies in this unique platform. This chart shows how its market valuation, based on expectations of success, is a multiple of its book value.
Market to book capitalization ratio for the market as a whole
Aileron Therapeutics is developing a new class of targeted cancer therapy drugs. The market valuation shown in this chart is based on the potential of their unique scientific platform. The dynamics reflect investor expectations for clinical trials.
Debts of the company, segment and market as a whole
ALRN - Company debts Aileron Therapeutics
Aileron Therapeutics, a biotech company, is using its financial resources to develop new drugs after shifting its strategy. This chart illustrates how the company, having abandoned previous programs, is trying to find a new promising molecule or technology, which requires careful management of its remaining capital.
Market segment debts - Oncology targeted therapy
Aileron Therapeutics is a biotech company that, after setbacks in oncology, pivoted to treating rare diseases. This chart shows how its debt policy reflects this strategic shift and how it is using its capital to fund entirely new research programs in an attempt to find successful applications for its scientific platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aileron Therapeutics
Arcadium Lithium, the merger formed, is one of the world's largest lithium producers. Lithium mining and processing is an extremely capital-intensive process. This chart shows the significant debt burden required to operate and expand global production capacity.
Market segment debt to market segment book capitalization - Oncology targeted therapy
Aileron Therapeutics is a clinical-stage biotech developing a new class of drugs to protect against the side effects of chemotherapy. This chart compares its debt load to the overall market capitalization of the oncology sector. It shows how the company is funding its clinical trials.
Debt to book value of all companies in the market
Aileron Therapeutics is developing a new class of drugs designed to protect healthy cells during chemotherapy. This is a critical issue in oncology. This graph of total market debt helps understand the financial environment in which the company is raising capital for clinical trials that could significantly improve the quality of life for cancer patients.
P/E of the company, segment and market as a whole
P/E - Aileron Therapeutics
For Aileron Therapeutics, an oncology company, the P/E ratio is not applicable. The company has no profit, and its valuation on this chart is arbitrary. It is a speculative bet that its unique approach to cancer treatment will prove safe and effective in clinical trials.
P/E of the market segment - Oncology targeted therapy
Aileron Therapeutics is a biotech company developing a new class of drugs called stabilized peptides for the treatment of cancer and other diseases. This chart shows the average valuation for the oncology sector, reflecting how investors value companies with innovative and risky technology platforms.
P/E of the market as a whole
Aileron Therapeutics is developing a new class of drugs called "stabilized peptides" for the treatment of cancer and other diseases. The company's approach aims to restore the function of tumor suppressor proteins. This risk appetite chart helps understand how investors evaluate innovative therapeutic platforms.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aileron Therapeutics
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein to protect against the side effects of chemotherapy. This graph reflects market expectations regarding the success of this innovative concept. Future revenue depends on the results of clinical trials.
%20P%2FE%20Aileron%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aileron-Therapeutics&v=1772513891916 "Chart of the company's future (projected) P/E Aileron Therapeutics")
Future (projected) P/E of the market segment - Oncology targeted therapy
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein for the treatment of cancer. This chart reflects how investors view its unique, yet risky, scientific approach. It compares expectations for Aileron with those of other early-stage oncology companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772513891957 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
Aileron Therapeutics is developing a new class of drugs that selectively protect healthy cells during chemotherapy. The company's success depends on the results of clinical trials. This graph, reflecting market optimism, influences investor willingness to fund innovative approaches in oncology that could improve patients' quality of life.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513891996 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aileron Therapeutics
Aileron Therapeutics is a clinical-stage biopharmaceutical company developing drugs to protect healthy cells from chemotherapy. Its financial performance is driven by R&D expenses. This chart illustrates the company's financial trajectory as it strives to create a new standard of supportive care in oncology.
Profit of companies in the market segment - Oncology targeted therapy
Aileron Therapeutics is developing a new class of drugs called stabilized peptides for the treatment of cancer and other diseases. This graph, showing overall profitability in the sector, reflects the search for breakthrough therapeutic approaches. Success of Aileron's platform could pave the way for treatments using previously inaccessible targets and fundamentally change the industry.
Overall market profit
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein for the treatment of cancer. This is a fundamental approach to oncology. The company's value is determined by the potential of its scientific platform, making it dependent on research results rather than market conditions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aileron Therapeutics
Aileron Therapeutics is developing a new class of drugs to protect healthy cells during chemotherapy. Future revenue projections are speculative and depend on the success of clinical trials. Analysts are evaluating the potential of its technology to improve cancer treatment.
%20profit%20of%20the%20company%20Aileron%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aileron-Therapeutics&v=1772513892083 "Graph of future (projected) profit of the company Aileron Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein to selectively kill cancer cells. This chart shows future revenue expectations for the entire targeted cancer therapy segment. It allows one to assess how the company's fundamental scientific approach to oncology fits into the overall outlook for this cutting-edge field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772513892091 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
Aileron Therapeutics is developing a new class of drugs that protect healthy cells during chemotherapy. This is an important supportive therapy. This chart, reflecting the investment climate, is important for Aileron. During periods of growth, investors are more willing to fund biotech companies working to improve the quality of life for cancer patients.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513892125 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aileron Therapeutics
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein for the treatment of cancer. For a clinical-stage biotech company, this metric, which correlates market capitalization with minimum revenue, reflects pure potential. It demonstrates investor confidence in its innovative scientific approach to oncology.
P/S market segment - Oncology targeted therapy
Aileron Therapeutics is developing a new class of drugs called stapins, which activate the p53 protein to selectively kill cancer cells. This approach could be applicable to a wide range of tumors. This chart shows the market premium the company is willing to pay for revenue in the oncology sector, demonstrating confidence in the breakthrough potential of Aileron's scientific platform.
P/S of the market as a whole
Aileron Therapeutics is developing a new class of drugs called stabilized peptides for the treatment of cancer and other diseases. This chart, showing the average revenue estimate, highlights that investors value the company based on the potential of its unique scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aileron Therapeutics
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein to protect patients from the side effects of chemotherapy. This chart shows the market's estimate of its potential future revenue, reflecting investor confidence in the success of its unique approach and commercial potential in maintenance cancer therapy.
%20P%2FS%20Aileron%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aileron-Therapeutics&v=1772513892233 "The graph of the company's future (projected) P/S Aileron Therapeutics")
Future (projected) P/S of the market segment - Oncology targeted therapy
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein for the treatment of cancer. The chart shows the average estimated future sales in the targeted oncology sector. It helps understand how investors view the company's scientific approach and its potential to develop breakthrough therapies targeting one of the key mechanisms of cancer defense.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772513892261 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
Aileron Therapeutics (ALRN) is a biotech company developing a new class of drugs to protect against the side effects of chemotherapy. Their potential depends on the success of clinical trials. This graph does not reflect their unique potential to improve the quality of life for cancer patients.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513892353 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aileron Therapeutics
Aileron Therapeutics is a clinical-stage biotech company with no sales revenue. It is focused on developing a new class of drugs that protect healthy cells during chemotherapy. The graph reflects future revenue from licensing or partnerships for its drug candidates.
Sales of companies in the market segment - Oncology targeted therapy
Aileron Therapeutics is an oncology company developing drugs that protect healthy cells from chemotherapy. Currently in the clinical stage, it has no revenue yet. Its future revenue will depend on the success of its lead candidate, which aims to improve the tolerability of cancer treatments.
Overall market sales
Aileron Therapeutics, Inc. is a biotech company developing a new class of drugs to protect against the side effects of chemotherapy. Its success depends on the results of clinical trials. Demand for these supportive drugs is linked to the number of cancer patients. The overall economics, reflected in this graph, influences healthcare funding overall.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aileron Therapeutics
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein to protect healthy cells during chemotherapy. Future revenue depends on the success of this concept. This chart reflects analysts' long-term expectations for its research.
%20sales%20of%20the%20company%20Aileron%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aileron-Therapeutics&v=1772513892434 "Schedule of future (projected) sales of the company Aileron Therapeutics")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein to protect against the side effects of chemotherapy. This chart shows the outlook for the targeted oncotherapy sector. It reflects the need not only for cancer treatment but also for improving patients' quality of life, a niche area for Aileron.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772513892484 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
This chart reflects the biotech investment climate, which is critical for Aileron Therapeutics. The company is developing a new class of drugs to protect against the side effects of chemotherapy. Raising funding to bring such innovations to market is directly dependent on the overall economic outlook and investor confidence.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513892522 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aileron Therapeutics
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein to protect healthy cells during chemotherapy. This chart reflects its status in clinical trials. Future profitability depends on successfully demonstrating the clinical benefit of this innovative approach.
Market segment marginality - Oncology targeted therapy
Aileron Therapeutics is a biopharmaceutical company developing a new class of p53-stabilizing drugs for the treatment of oncology. Profitability depends on the success of its unique approach in clinical trials. This chart shows the average profitability in the pharmaceutical industry, providing context for assessing the potential of Aileron's innovative technology.
Market marginality as a whole
Aileron Therapeutics is developing a new class of drugs that selectively protect healthy cells during chemotherapy. As a research-stage company, it relies on funding and clinical data. This chart reflects the overall investment climate, which determines the availability of capital for biotech companies working on supportive care in oncology.
Employees in the company, segment and market as a whole
Number of employees in the company Aileron Therapeutics
Aileron Therapeutics is a biotech company developing a new class of drugs to protect against the side effects of chemotherapy. This graph shows a compact scientific team. A small staff is typical for clinical-stage companies. Changes in the graph may reflect progress or pauses in trials depending on the results.
Share of the company's employees Aileron Therapeutics within the market segment - Oncology targeted therapy
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein to protect healthy cells during chemotherapy. This chart shows the company's share of the total number of scientists working in the field of targeted oncology. This reflects its innovative approach to improving the tolerability of cancer treatments.
Number of employees in the market segment - Oncology targeted therapy
Aileron Therapeutics is developing a new class of drugs called stapins to protect healthy cells from chemotherapy. This chart, showing activity in the targeted oncology sector, is important. The growing number of scientists working on supportive care in oncology demonstrates a commitment to improving patients' quality of life and treatment tolerability.
Number of employees in the market as a whole
Aileron Therapeutics is developing a new class of drugs that protect healthy cells during chemotherapy. This overall employment chart reflects the economy's ability to finance advanced medicine. Only with stable growth is long-term investment in R&D aimed at improving the quality of life for cancer patients possible.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aileron Therapeutics (ALRN)
Aileron Therapeutics (ALRN) is a biopharmaceutical company developing a new class of drugs (peptide stabilizers) for the treatment of cancer. This is a classic R&D business. The entire market value is a bet by investors on their scientific platform. This chart reflects the high valuation of this "intellectual capital."
%20of%20the%20company%20Aileron%20Therapeutics%20(ALRN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aileron-Therapeutics-ALRN&v=1772513892692 "Chart of market capitalization per employee (in thousands of dollars) of the company Aileron Therapeutics (ALRN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Aileron Therapeutics is developing a new class of drugs designed to protect healthy cells during chemotherapy. This is an innovative concept in oncology. The chart helps us understand the enormous market value that can be placed on a breakthrough scientific idea being developed by a small team of researchers.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772513892695 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Aileron Therapeutics is developing a new class of drugs that stabilize the p53 protein for cancer treatment. This is a fundamentally new approach in oncology. This chart shows a very high valuation per employee, as the market cap reflects the potential of breakthrough science being developed by a small but highly qualified team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513892699 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aileron Therapeutics (ALRN)
Aileron Therapeutics is a biotech company that, after a series of failures in oncology, has focused on developing drugs for rare diseases. This chart shows the "cost of rebooting" R&D: how much the company spends (negative profit) on each employee trying to find a new, successful R&D program.
%20Chart%20Aileron%20Therapeutics%20(ALRN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aileron-Therapeutics-ALRN&v=1772513892701 "Company Profit Per Employee (in thousands of dollars) Chart Aileron Therapeutics (ALRN)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Aileron Therapeutics is developing a new class of drugs to protect against the side effects of chemotherapy. For a biotech company in the development stage, this chart shows the efficiency of capital expenditure. Successful clinical trials and subsequent approval of the drug could dramatically change this metric, converting costs into significant profits.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772513892705 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Aileron Therapeutics (ALRN) is a clinical-stage biopharmaceutical company developing a new class of drugs (p53 stabilizers) for the treatment of cancer. It is an R&D company with no profit. This metric is negative and reflects the "cost" of a single scientist working in the complex field of oncology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513892730 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aileron Therapeutics (ALRN)
Aileron Therapeutics is developing a new class of drugs to protect against the side effects of chemotherapy. Revenue may not be generated during the clinical development stage. This chart is important as an indicator of potential: a successful drug could find widespread use and generate significant revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aileron-Therapeutics-ALRN&v=1772513892752 "Sales chart per company employee Aileron Therapeutics (ALRN)")
Sales per employee in the market segment - Oncology targeted therapy
Aileron Therapeutics is a clinical-stage biotech company developing drugs to protect patients from the side effects of chemotherapy. This is an R&D company. This chart reflects their clinical stage. Their research team's productivity lies in developing and advancing drug candidates, not in ongoing sales.
Sales per employee for the market as a whole
Barrett Business Services (BBSI) is a professional outsourcing company (PEO). They provide HR, payroll, and insurance services for small and medium-sized businesses. They are a people-to-people service business. This chart shows how effectively BBSI scales its services. This increase means each BBSI consultant can serve more clients.
Short shares by company, segment and market as a whole
Shares shorted by company Aileron Therapeutics (ALRN)
Aileron (ALRN) is an oncology company that has repeatedly shifted focus after failures. This chart tracks bearish bets. "Shorts" are betting that the company's new strategy will also fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aileron-Therapeutics-ALRN&v=1772513892846 "Short Shares Chart for the Company Aileron Therapeutics (ALRN)")
Shares shorted by market segment - Oncology targeted therapy
Aileron (ALRN) is a biotech company developing drugs to protect patients during chemotherapy. The chart below shows the overall short position in the oncology biotech sector. It reflects the degree of investor skepticism about the commercial potential of maintenance therapy.
Shares shorted by the overall market
Aileron (ALRN) is a clinical-stage biotech. Its value reflects the hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse that require refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aileron Therapeutics (ALRN)
This chart for Aileron is a barometer of biotech speculation. The company has shifted focus and is now developing new drugs for lung diseases. "Overheating" (above 70) occurs with announcements of new preclinical programs. A history of past failures (in oncology) and early-stage development lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aileron-Therapeutics-ALRN&v=1772513892894 "RSI 14 indicator chart for the company's stock Aileron Therapeutics (ALRN)")
RSI 14 Market Segment - Oncology targeted therapy
Aileron is a "biotech" company, a "shield" against chemotherapy. Their "thing" is drugs (ALRN-6924) that *protect* healthy cells from the *toxicity* of chemotherapy. The "Oncology targeted therapy" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of *the entire* segment. It helps us understand: is ALRN's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Aileron Therapeutics (ALRN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ALRN (Aileron Therapeutics)
Aileron Therapeutics develops drugs designed to protect healthy cells during chemotherapy. This chart shows the analysts' average 12-month forecast, representing their collective speculative bet that the company's R&D platform will prove effective in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ALRN-Aileron-Therapeutics&v=1772513892922 "A chart showing analyst consensus forecasts for the expected stock price. ALRN (Aileron Therapeutics)")
The difference between the consensus estimate and the actual stock price ALRN (Aileron Therapeutics)
Aileron Therapeutics (ALRN) is an oncology company developing drugs designed to "protect" healthy cells during chemotherapy. This chart shows the difference between the market valuation and the consensus forecast. It highlights the potential (and risks) analysts see in this R&D platform, which aims to improve the tolerability of cancer treatments.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ALRN-Aileron-Therapeutics&v=1772513892950 "A chart showing the difference between the consensus forecast and the actual stock price. ALRN (Aileron Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
Aileron is a clinical-stage biotech company developing targeted cancer drugs. This is speculative R&D. This chart shows analysts' overall expectations for the entire oncology sector. It reflects whether experts believe in new R&D breakthroughs or anticipate a "winter" in biotech funding.
Analysts' consensus forecast for the overall market share price
Aileron Therapeutics (ALRN) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer treatment. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It is an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aileron Therapeutics
Aileron is a biotech R&D company focused on oncology. Their R&D pipeline is aimed at developing stabilizing peptides for cancer treatment. It's a binary risk business. This chart is a pure indicator of their faith in R&D. It doesn't reflect revenue, but rather a speculative valuation of their (very risky) pipeline and their clinical trial data.
AKIMA Market Segment Index - Oncology targeted therapy
Aileron Therapeutics is working on a complex problem in oncology. They are developing drugs that protect healthy cells during chemotherapy. This targeted therapy aims to improve quality of life. This chart compares their composite index to the sector, showing how their approach compares to other biotechs.
The AKIM Index for the overall market
Aileron Therapeutics is a biopharmaceutical company that has refocused on treating orphan lung diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how the ALRN (Rein Therapeutics), which is shifting its strategy, compares to overall economic trends.
